NCT01783197 2023-08-04
Study of Selumetinib in Patients With Previously Treated or Untreated Advanced/Metastatic NSCLC
Canadian Cancer Trials Group
Phase 1 Completed
Canadian Cancer Trials Group
OHSU Knight Cancer Institute
The Christie NHS Foundation Trust
Cancer Research UK
AstraZeneca